Skip to main content
Publications
Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X, Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01). Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Berghea F, Pentek M, Keat A, Severens JL, Fautrel B, Boonen A. Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. RMD open. 2017 Sep 4;3(2):E000453. doi: 10.1136/rmdopen-2017-000453